Labcorp to buy select assets from Opko Health unit for up to $872 million
Labcorp will acquire BioReference Health lab testing operations from Opko Health for $722M, with a potential $150M additional payment. The deal includes 80 patient service centers and the 4Kscore prostate cancer test, expected to generate $250M in revenue post-closing. Opko shares rose 20% premarket. The transaction requires regulatory approval.
How this was made
The 30-second read
Why it matters
The deal adds significant revenue and service capabilities to Labcorp while providing Opko shareholders a premium cash payout and upside from the 4Kscore earn‑out.
Market read
The transaction is a material M&A event in the healthcare sector, likely moving both LH and OPK stocks and influencing broader diagnostics industry sentiment.
What to watch
Regulatory clearance and the earn‑out tied to 4Kscore test performance introduce execution risk that may temper upside.
Background
Labcorp (LH) is expanding its laboratory testing portfolio by acquiring Opko Health's (OPK) BioReference Health unit, which includes the 4Kscore prostate‑cancer test. Opko will retain its biopharma pipeline, focusing on the kidney‑disease drug Rayaldee.
Ticker impact
Opko Health announced the sale of its BioReference Health assets to Labcorp for up to $872 million, sending Opko shares up 20% in pre‑market trading.
upward pressure as investors price the cash premium and revenue upside from the 4Kscore test.
The transaction adds $250 million of revenue in year one and includes a $150 million earn‑out tied to the 4Kscore test, which the market views as value‑creating.
Labcorp disclosed a $722 million cash acquisition of Opko's BioReference Health operations, expanding its testing footprint.
potential slight dip as the market evaluates the financing impact of the $722 million purchase.
While the deal adds over 80 service centers, the cash cost and regulatory uncertainty could temper enthusiasm.
Market effects
Consolidation in the clinical diagnostics sector may spur further M&A activity among testing providers.
U.S. healthcare services stocks could see modest re‑rating as investors assess deal synergies.
The transaction highlights growing demand for advanced prostate‑cancer diagnostics, a trend relevant to global biotech investors.
Counterpoint
Labcorp's cash‑heavy acquisition could strain its balance sheet, making the stock vulnerable if integration costs exceed expectations.
Key entities
- CompanyLabcorp
U.S. clinical laboratory services provider acquiring Opko assets.
- CompanyOpko Health
Biopharma and diagnostics company selling its BioReference Health unit.
